AUTHOR=Fei Yanqing , Shi Ruting , Song Zhi 

TITLE=Adjunctive Treatment With Eslicarbazepine Acetate for Adults and Children With Focal-Onset Epilepsy: A Meta-Analysis

JOURNAL=Frontiers in Neurology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.909471

DOI=10.3389/fneur.2022.909471

ISSN=1664-2295

ABSTRACT=<sec><title>Background</title><p>The efficacy and tolerability of eslicarbazepine acetate (ESL) in adults and children with focal-onset epilepsy (FOE) according to the dose remain to be validated. A meta-analysis based on randomized controlled trials (RCTs) was therefore conducted as a summary.</p></sec><sec><title>Methods</title><p>Relevant RCTs were collected by systematic searching the electronic databases of PubMed, Cochrane's Library, Embase, Wanfang and CNKI from inception to May 16, 2022. The random-effect model was adopted to pool the results by incorporating the possible heterogeneity. Efficacy outcomes including responsive rate and effective rate, defined as cases with 50 and ≥75% reduction in seizure frequency compared to baseline, were determined, respectively. Incidence of severe adverse events (AE) leading to drug discontinuation was also evaluated.</p></sec><sec><title>Results</title><p>Ten studies including 2,565 people with epilepsy contributed to the meta-analysis. For adults, ESL 400 mg/d did not improve the response rate or the effective rate; ESL 800 mg/d was associated with improved response rate (odds ratio [OR] 2.16, 95% confidence interval [CI]: 1.65–2.83, <italic>p</italic> &lt; 0.001) and effective rate (OR 2.16, 95% CI: 1.41–3.30, <italic>p</italic> &lt; 0.001) without significantly increased severe AE (OR 1.58, 95% CI: 0.90–2.78, <italic>p</italic> = 0.11); ESL 1,200 mg/d improved response rate (OR 2.49, <italic>p</italic> &lt; 0.001) and effective rate (OR 3.09, <italic>p</italic> = 0.04), but significantly increased severe AE (OR 3.72, <italic>p</italic> &lt; 0.001). For children, ESL also did not significantly improve the response rate (OR 1.76, <italic>p</italic> = 0.22) or the effective rate (OR 2.17, <italic>p</italic> = 0.13).</p></sec><sec><title>Conclusion</title><p>ESL 800 mg/d is effective and well-tolerated as adjuvants for adults with FOE. Efficacy of ESL in children with FOE should be further evaluated.</p></sec>